FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan List

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Procedures

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Lori N Griner; Joseph O Johnson; Alan F List; Kathy L McGraw; Gary W Reuther
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.
Mikkael A Sekeres; Ali Tabarroki; Ramon Tiu; Valeria Visconte; Hideki Makishima; Jennifer Paleveda; Ronald Paquette; Anjali S Advani; Manuel Afable; David Cuthbertson; Ricki Englehaupt; Andres Jerez; Joyce Juersivich; Rami S Komrokji; Jeffrey E Lancet; Alan F List; Jaroslaw P Maciejewski
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Alan F List
New therapeutics for myelodysplastic syndromes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan List (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lori N Griner; Joseph O Johnson; Alan F List; Kathy L McGraw; Gary W Reuther
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.
British journal of haematology 2013;160(2):177-87.
2012: Mikkael A Sekeres; Ali Tabarroki; Ramon Tiu; Valeria Visconte; Hideki Makishima; Jennifer Paleveda; Ronald Paquette; Anjali S Advani; Manuel Afable; David Cuthbertson; Ricki Englehaupt; Andres Jerez; Joyce Juersivich; Rami S Komrokji; Jeffrey E Lancet; Alan F List; Jaroslaw P Maciejewski
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Blood 2012;120(25):4945-51.
2012: Alan F List
New therapeutics for myelodysplastic syndromes.
Leukemia research 2012;36(12):1470-4.
2012: Rami S Komrokji; Jeffrey E Lancet; Najla H Al Ali; Maria Corrales-Yepez; Pearlie K Epling-Burnette; Mohamed A Kharfan-Dabaja; Eric Padron; Javier Pinilla-Ibarz; Dana E Rollison; Ling Zhang; Alan F List
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.
American journal of hematology 2012;87(11):1006-9.
2012: Rami S Komrokji; Jeffrey E Lancet; Nianhang Chen; Richard Lush; Jennifer Paleveda; Hussain I Saba; Arlene S Swern; Alan F List
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
Blood 2012;120(17):3419-24.
2012: Alan F List; Noelia Martinez-Lopez; Carole Paley; Azra Raza; David P Steensma; Maria R Baer; Jason Esposito; John Feigert; Emmanuel Besa
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(17):2134-9.
2012: Rami S Komrokji; Jeffrey E Lancet; Maria Corrales-Yepez; Teresa Fields; Mohammad Kharfan-Dabaja; Eric Padron; Najla Al Ali; Alan F List
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.
Cancer 2012;118(10):2659-64.
2012: Kathy L McGraw; Lubomir Sokol; Gisela C Caceres; Justine A Clark; Gwenny M Fuhler; Joseph O Johnson; Alan F List
Erythropoietin receptor signaling is membrane raft dependent.
PloS one 2012;7(4):e34477.
2012: Yuka Sugimoto; Hadrian Szpurka; Ramon Tiu; Fabiola Traina; Valeria Visconte; Manuel Afable; Kathryn Guinta; Anna Jankowska; Andres Jerez; Alan F List; Hideki Makishima; Kathy L McGraw; Christine L O'Keefe; Mikkael A Sekeres; Jaroslaw Maciejewski
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Journal of hematology & oncology 2012;5():4.
2011: Anna Jankowska; Alan F List; Eric D Hsi; Yun Huang; Hideki Makishima; A MICHAEL MCDEVITT; Christine L O'Keefe; Courtney Prince; Anjana Rao; Mikkael A Sekeres; Yuka Sugimoto; Hadrian Szpurka; Ramon Tiu; Fabiola Traina; Valeria Visconte; Jaroslaw P Maciejewski
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.
Blood 2011;118(14):3932-41.
2011: Rami S Komrokji; Alan F List
Role of lenalidomide in the treatment of myelodysplastic syndromes.
Seminars in oncology 2011;38(5):648-57.
2011: Mikkael A Sekeres; Cheryl L Willman; Deborah Mulford; Tom Norwood; Stephen H Petersdorf; Anjali Advani; Frederick R Appelbaum; Holly Gundacker; Jeffrey Lancet; Jane Liesveld; Alan F List
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
Blood 2011;118(3):523-8.
2011: Rami S Komrokji; Mikkael A Sekeres; Alan F List
Management of lower-risk myelodysplastic syndromes: the art and evidence.
Current hematologic malignancy reports 2011;6(2):145-53.
2011: Ramon Tiu; Lukasz Gondek; Christine L O'Keefe; Paul Elson; Jungwon Huh; Azim Mohamedali; Austin Kulasekararaj; Anjali Advani; Ronald Paquette; Alan F List; Mikkael A Sekeres; A MICHAEL MCDEVITT; Ghulam J Mufti; Jaroslaw P Maciejewski
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.
Blood 2011;117(17):4552-60.
2011: Celeste Bello; Daohai Yu; Rami S Komrokji; Weiwei Zhu; Gene A Wetzstein; Alan F List; Jeffrey E Lancet
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Cancer 2011;117(7):1463-9.
2011: Samantha L Price; Jeffrey E Lancet; Timothy J George; Gene A Wetzstein; Alan F List; Viet Q Ho; Hugo F Fernandez; Javier Pinilla-Ibarz; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Leukemia research 2011;35(3):301-4.
2011: Mikkael A Sekeres; David P Steensma; Arlene S Swern; Andrew Artz; John Huber; Alan F List; Jaroslaw P Maciejewski; Paul Scribner; Richard Stone
Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey.
The oncologist 2011;16(6):904-11.
2011: Mikkael A Sekeres; Christine O'Keefe; Alan F List; Katarina Paulic; Manuel Afable; Ricki Englehaupt; Jaroslaw P Maciejewski
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
American journal of hematology 2011;86(1):102-3.
2011: Jose Ortega; Rami Komrokji; Alan F List
The hematopoietic growth factors in the myelodysplastic syndromes.
Cancer treatment and research 2011;157():363-82.
2010: Hideki Makishima; Anna Jankowska; Ramon Tiu; Hadrian Szpurka; Y Sugimoto; Z Hu; Yogen Saunthararajah; K Guinta; M A Keddache; P Putnam; Mikkael A Sekeres; Alison R Moliterno; Alan F List; A MICHAEL MCDEVITT; Jaroslaw P Maciejewski
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.
Leukemia 2010;24(10):1799-804.
2010: Mikkael A Sekeres; Alan F List; David Cuthbertson; Ronald Paquette; Rebecca Ganetzky; Rebecca Ganetsky; Deborah Latham; Katarina Paulic; Manuel Afable; Hussain I Saba; Thomas P Loughran; Jaroslaw P Maciejewski
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(13):2253-8.
2010: M A Hartley; L Sokol; G Caceres; M A Hussein; Alan F List; Javier Pinilla-Ibarz
Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia.
Mediterranean journal of hematology and infectious diseases 2010;2(1):e2010002.
2009: Sandra E Kurtin; Alan F List
Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.
Clinical lymphoma & myeloma 2009;9(3):E10-3.
2008: Andrew Lamb; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan F List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre J Issa; Emil J Freireich; Guillermo Garcia-Manero
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Cancer 2008;113(6):1351-61.
2008: Magda Melchert; Alan F List
Targeted therapies in myelodysplastic syndrome.
Seminars in hematology 2008;45(1):31-8.
2008: Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles Alan Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Blood 2008;111(1):86-93.
2007: Jose Ortega; Alan F List
Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Current opinion in oncology 2007;19(6):656-9.
2007: Francis Giles; Alan F List; Michael Carroll; Jorge E Cortes; Joyce Valickas; Bee-Lian Chen; Eric Masson; Christian Jacques; Dirk Laurent; Maher Albitar; Eric J Feldman; Gail J Roboz
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Leukemia research 2007;31(7):891-7.
2007: P Fenaux; john bennett; D T Bowen; Robert D Knight; Alan F List
Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004.
Transfusion medicine (Oxford, England) 2007;17(3):151-60.
2007: Andrew Lamb; Francis Giles; Alan F List; Roger Lyons; Mikkael A Sekeres; Sherry Pierce; Robert Deuson; Joseph Leveque
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Cancer 2007;109(9):1705-14.
2006: Alan F List
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
Cancer control : journal of the Moffitt Cancer Center 2006;13 Suppl():12-6.
2006: Alan F List; Amanda F Baker; Sylvan Green; William T Bellamy
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
Cancer control : journal of the Moffitt Cancer Center 2006;13 Suppl():4-11.
2006: Vishakha Kale; Alan F List
Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes.
Current pharmaceutical biotechnology 2006;7(5):339-42.
2006: Amanda F Baker; William T Bellamy; W R Tate; W B Bair; R Heaton; Alan F List
Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndrome.
Leukemia 2006;20(9):1620-1.
2006: Francis Giles; William T Bellamy; Zeev Estrov; Susan M O'Brien; Srdan Verstovsek; Farhad Ravandi; Miloslav Beran; Paul Bycott; Yazdi K Pithavala; Heidi M Steinfeldt; Steven D Reich; Alan F List; Karen W L Yee
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Leukemia research 2006;30(7):801-11.
2006: Gary J Schiller; James Slack; John D Hainsworth; James Mason; Mansoor Saleh; David A Rizzieri; Dan Douer; Alan F List
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2456-64.
2006: Gail J Roboz; Francis Giles; Alan F List; Jorge E Cortes; R Carlin; M Kowalski; S Bilic; Eric Masson; M Rosamilia; Michael W Schuster; D Laurent; Eric J Feldman
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Leukemia 2006;20(6):952-7.
2006: Mikkael A Sekeres; Alan F List
Immunomodulation in myelodysplastic syndromes.
Best practice & research. Clinical haematology 2006;19(4):757-67.
2005: Mikkael A Sekeres; Alan F List
Alternative treatments for myelodysplastic syndromes.
Seminars in hematology 2005;42(3 Suppl 2):S32-7.
2005: Mikkael A Sekeres; Alan F List
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
Current hematology reports 2005;4(3):182-5.
2005: Alan F List; Sandy Kurtin; Denise J Roe; Andrew Buresh; Daruka Mahadevan; Deborah Fuchs; Lisa M Rimsza; Ruth Heaton; Robert Knight; Jerome B Zeldis
Efficacy of lenalidomide in myelodysplastic syndromes.
The New England journal of medicine 2005;352(6):549-57.
2004: M Nouzova; Nicholas Holtan; Marc M Oshiro; RB Isett; J L Munoz-Rodriguez; Alan F List; M L Narro; S J Miller; N C Merchant; Bernard W Futscher
Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.
The Journal of pharmacology and experimental therapeutics 2004;311(3):968-81.
2004: Daruka Mahadevan; Alan F List
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies.
Blood 2004;104(7):1940-51.
2004: Alan F List; Betty Glinsmann-Gibson; Chad Stadheim; Emmanuelle J Meuillet; William T Bellamy; Garth Powis
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
Experimental hematology 2004;32(6):526-35.
2003: Alan F List; M Beran; J DiPersio; J Slack; N Vey; C S Rosenfeld; P Greenberg
Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
Leukemia 2003;17(8):1499-507.
2003: Robert T Dorr; A Briggs; P Kintzel; R Meyers; H-H S Chow; Alan F List
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Bone marrow transplantation 2003;31(8):643-9.
2002: Alan F List; Kenneth J Kopecky; Cheryl L Willman; David R Head; Marilyn L Slovak; Dan Douer; Shaker R Dakhil; Frederick R Appelbaum
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase.
Blood 2002;100(5):1910-2.
2002: Herson I Quiñones; Alan F List; Eugene W Gerner
Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1295-300.
2002: Alan F List
New approaches to the treatment of myelodysplasia.
The oncologist 2002;7 Suppl 1():39-49.
2001: Alan F List; Kenneth J Kopecky; Cheryl L Willman; David R Head; Diane L Persons; Marilyn L Slovak; R Dorr; Chatchada Karanes; HE Hynes; James Doroshow; M Shurafa; Frederick R Appelbaum
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
Blood 2001;98(12):3212-20.
2001: J E Dodge; C Munson; Alan F List
KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients.
Leukemia research 2001;25(10):917-25.
2001: R Dorr; Chatchada Karanes; C Spier; Thomas M Grogan; J Greer; J Moore; B Weinberger; G Schiller; T Pearce; Litchman Manuel; W Dalton; D Roe; Alan F List
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1589-99.
2001: William T Bellamy; Lynne Richter; D Sirjani; CR Roxas; Betty Glinsmann-Gibson; Yvette M Frutiger; Thomas M Grogan; Alan F List
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.
Blood 2001;97(5):1427-34.
2001: Alan F List
Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies.
The oncologist 2001;6 Suppl 5():24-31.
2000: Alan F List; Eugene W Gerner
Amifostine: a tonic or toxin to myeloid progenitors.
Leukemia research 2000;24(12):1009-11.
2000: Lisa M Rimsza; Kenneth J Kopecky; J Ruschulte; I-Ming Chen; Marilyn L Slovak; Chatchada Karanes; John E Godwin; Alan F List; Cheryl L Willman
Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature.
Leukemia 2000;14(6):1044-51.
2000: Alan F List; Richard T Maziarz; Patrick J Stiff; J Jansen; J Liesveld; F Andrews; M Schuster; Steven Neil Wolff; M Litzow; Chatchada Karanes; Seth Dahlberg; B Kirkhart; J A Bianco; jack w singer
A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
Bone marrow transplantation 2000;25(3):283-91.
1999: Alan F List
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
Seminars in oncology 1999;26(2 Suppl 7):61-5.
1999: Alan F List
Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes.
Forum (Genoa, Italy) 1999;9(1):35-45.
1999: Alan Marshall Miller; W E Noyes; Raymond M Taetle; Alan F List
Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome.
Leukemia research 1999;23(1):77-83.
1998: J E Dodge; Alan F List; Bernard W Futscher
Selective variegated methylation of the p15 CpG island in acute myeloid leukemia.
International journal of cancer. Journal international du cancer 1998;78(5):561-7.
1998: Alan F List; R Heaton; Betty Glinsmann-Gibson; RL Capizzi
Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors.
Leukemia 1998;12(10):1596-602.
1998: Alan F List
Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
Leukemia research 1998;22 Suppl 1():S7-11.
1998: Donald C Doll; L M Kasper; Raymond M Taetle; Alan F List
Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes.
Leukemia research 1998;22(1):7-12.
1997: Alan F List; F Brasfield; R Heaton; Betty Glinsmann-Gibson; L Crook; Raymond M Taetle; RL Capizzi
Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
Blood 1997;90(9):3364-9.
1997: Alan F List
Non-P-glycoprotein drug export mechanisms of multidrug resistance.
Seminars in hematology 1997;34(4 Suppl 5):20-4.
1997: Charles W Taylor; L M Wang; Alan F List; D Fernandes; Gillian Paine-Murrieta; C S Johnson; RL Capizzi
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
European journal of cancer (Oxford, England : 1990) 1997;33(10):1693-8.
1996: Alan F List; R Heaton; Betty Glinsmann-Gibson; R L Capizzi
Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
Seminars in oncology 1996;23(4 Suppl 8):58-63.
1996: Alan F List
Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
Leukemia 1996;10(6):937-42.
1996: Alan F List
The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
Leukemia 1996;10 Suppl 1():S36-8.
1996: Alan F List; C S Spier; Thomas M Grogan; C Johnson; Denise J Roe; J P Greer; Steven Neil Wolff; Henk J Broxterman; G L Scheffer; R J Scheper; William S Dalton
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
Blood 1996;87(6):2464-9.
1996: A Samdani; U Vijapurkar; M A Grimm; C S Spier; T M Grogan; Betty Glinsmann-Gibson; Alan F List
Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).
Leukemia research 1996;20(2):175-80.
1994: M Russell; Alan F List; P Greenberg; S Woodward; B Glinsmann; E Parganas; J Ihle; Raymond M Taetle
Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
Blood 1994;84(4):1243-8.
1994: Betty Glinsmann-Gibson; C Spier; M Baier; Raymond M Taetle; V C Broudy; Alan F List
Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome.
Leukemia 1994;8(5):827-32.
1994: L Glasser; R L Fiederlein; M Wood; William S Dalton; Alan F List
Hematopoietic progenitor cell content of bone marrow harvests: relative contributions of blood and bone marrow.
Progress in clinical and biological research 1994;389():621-30.
1993: Alan F List; C M Spier; Thomas P Miller; Thomas M Grogan
Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.
Leukemia 1993;7(3):398-403.
1992: Alan F List; A Jacobs
Biology and pathogenesis of the myelodysplastic syndromes.
Seminars in oncology 1992;19(1):14-24.
1991: W H Kreisle; D S Alberts; Alan F List; T McCloskey; P Plezia; Yei-Mei Peng; M George
A phase I trial of 14-day continuous intravenous infusion mitoxantrone.
Anti-cancer drugs 1991;2(3):251-9.